Abstract
Plant-derived nucleic acids, especially small RNAs, have demonstrated significant pharmacological potential in macrophage-mediated anti-tumor, immune-regulating, and antiviral therapies. This review explores the evidence for cross-kingdom regulation by plant-derived mRNAs and miRNAs, their therapeutic potential, and the delivery strategies using macrophages and natural exosome vehicles. It provides a foundation for plant-derived RNAs as a next generation of nucleic acid-based biotherapies.
Introduction: The Frontier of Cross-Kingdom Regulation
While traditionally viewed as simple dietary components, recent evidence suggests that plant nucleic acids (miRNAs, mRNAs, and tRNAs) can survive digestion, enter the mammalian bloodstream, and regulate host genes. This process, termed "cross-kingdom regulation," opens new avenues for therapy. However, developing these molecules as "biodrugs" faces challenges such as environmental instability and low bioavailability. This paper synthesizes research on how plant RNAs interact with the mammalian immune system—specifically macrophages—to evaluate their potential as clinical therapies.
Mechanisms of Action and Biogenesis
Plant-derived RNAs interfere with mammalian signaling pathways through functional mimicry. For example, certain plant miRNAs can bind to human TLR3 receptors or target the Wnt signaling pathway to inhibit cancers. The stability of these molecules is often attributed to their packaging in exosome-like nanovesicles, which protect them from the acidic stomach environment and blood RNases.
Therapeutic Applications in Immune Modulation
The therapeutic successes of plant RNAs span anti-tumor, anti-inflammatory, and antiviral domains. Notable examples include:
- Anti-Tumor: Soybean-derived gma-miR159a targets the TCF7 transcription factor to reduce breast tumor growth.
- Anti-Inflammatory: Ginger-derived exosomal RNAs induce IL-22 production, improving intestinal barrier function in colitis models.
- Antiviral: Honeysuckle-derived miR2911 has shown efficacy in inhibiting Influenza A, SARS-CoV-2, and Enterovirus 71.
Delivery Strategies: The Macrophage "Trojan Horse"
Macrophages serve as both targets and delivery vehicles. They naturally scavenge plant-derived extracellular vesicles and can migrate to sites of inflammation or tumors. This "Trojan Horse" mechanism allows for localized drug delivery. Furthermore, plant-derived exosome-like nanovesicles (PENs) are highlighted as superior to synthetic platforms due to their high bioavailability and low immunogenicity.
Challenges and Future Directions
Several "bottlenecks" remain before clinical application:
- Standardization: High-purity extraction technologies for plant RNAs are needed.
- Dosing: Determining the "minimum effective dose" is difficult due to low detected concentrations in mammalian tissues.
- Mapping: A systematic "plant nucleic acid gene library" is required to map plant RNA targets to human genes.
- Tracking: Advanced hybridization technologies are necessary to track these molecules' localization within the body.
Summary updated